Mondello P, et al. - Researchers performed a retrospective analysis to assess the patients with follicular lymphoma grade 3A (FL3A) treated with either rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) or Rituximab plus bendamustine (R-B) in five European cancer centers and compare their outcomes. Compared to R-CHOP, R-B as the first-line treatment of FL3A was better tolerated and appeared to produce more intense responses, leading to a significantly reduced relapse rate and prolonged progression-free survival (PFS). Therefore, for FL grade 3A, R-B proved a valid treatment option.